The DNA repair‐associated resistance mechanisms to PARP inhibition have been well characterized in breast and ovarian cancers (D'Andrea, 2018), and it is reasonable to predict that similar mechanisms may promote resistance in CRC patients following PARP blockade. This evidence concerns the gene PARP1 and colorectal carcinoma.